FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079433130> ?p ?o ?g. }

• W2079433130 endingPage "1382" @default.
• W2079433130 startingPage "1373" @default.
• W2079433130 abstract "Abstract Purpose: Goal of this study was to identify mechanisms that limit efficacy of trabectedin (ET-743, Yondelis) in Ewing sarcoma (EWS), so as to develop a clinical applicable combination therapy. Experimental Design: By chromatin immunoprecipitation, we analyzed EWS–FLI1 binding to the promoters of several target genes, such as TGFβR2, CD99, insulin-like growth factor receptor 1 (IGF1R), and IGF1, both in vitro and in xenografts treated with trabectedin or doxorubicin. Combined therapy with trabectedin and anti-IGF1R agents (AVE1642 HAb; OSI-906) was tested in vitro and in xenografts. Results: We confirm that both trabectedin and doxorubicin were able to strongly reduce EWS–FLI1 (both type I and type II) binding to two representative target genes (TGFβR2 and CD99), both in vitro and in xenografts. However, trabectedin, but not doxorubicin, was also able to increase the occupancy of EWS–FLI1 to IGF1R promoters, leading to IGF1R upregulation. Inhibition of IGF1R either by the specific AVE1642 human antibody or by the dual IGF1R/insulin receptor inhibitor OSI-906 (Linsitinib) greatly potentiate the efficacy of trabectedin in the 13 EWS cell lines here considered as well as in TC-71 and 6647 xenografts. Combined therapy induced synergistic cytotoxic effects. Trabectedin and OSI-906 deliver complementary messages that likely converge on DNA-damage response and repair pathways. Conclusions: We showed that trabectedin may not only inhibit but also enhance the binding of EWS–FLI1 to certain target genes, leading to upregulation of IGF1R. We here provide the rationale for combining trabectedin to anti-IGF1R inhibitors. Clin Cancer Res; 21(6); 1373–82. ©2015 AACR." @default.
• W2079433130 created "2016-06-24" @default.
• W2079433130 creator A5015636061 @default.
• W2079433130 creator A5022969007 @default.
• W2079433130 creator A5025533934 @default.
• W2079433130 creator A5040594896 @default.
• W2079433130 creator A5044250695 @default.
• W2079433130 creator A5052266547 @default.
• W2079433130 creator A5055703421 @default.
• W2079433130 creator A5067193071 @default.
• W2079433130 creator A5072885632 @default.
• W2079433130 creator A5077480042 @default.
• W2079433130 creator A5079394240 @default.
• W2079433130 creator A5083948167 @default.
• W2079433130 creator A5085470464 @default.
• W2079433130 creator A5089369408 @default.
• W2079433130 creator A5090686010 @default.
• W2079433130 date "2015-03-12" @default.
• W2079433130 modified "2023-10-01" @default.
• W2079433130 title "Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents" @default.
• W2079433130 cites W1536937502 @default.
• W2079433130 cites W1832532883 @default.
• W2079433130 cites W1972809568 @default.
• W2079433130 cites W1977139727 @default.
• W2079433130 cites W1985905712 @default.
• W2079433130 cites W1990430867 @default.
• W2079433130 cites W1992059152 @default.
• W2079433130 cites W2005532023 @default.
• W2079433130 cites W2005675755 @default.
• W2079433130 cites W2008124412 @default.
• W2079433130 cites W2018169190 @default.
• W2079433130 cites W2025883606 @default.
• W2079433130 cites W2030372367 @default.
• W2079433130 cites W2044313879 @default.
• W2079433130 cites W2049025598 @default.
• W2079433130 cites W2055854406 @default.
• W2079433130 cites W2060932390 @default.
• W2079433130 cites W2065600610 @default.
• W2079433130 cites W2069351898 @default.
• W2079433130 cites W2075561524 @default.
• W2079433130 cites W2076993664 @default.
• W2079433130 cites W2086849370 @default.
• W2079433130 cites W2090073404 @default.
• W2079433130 cites W2090915824 @default.
• W2079433130 cites W2097977881 @default.
• W2079433130 cites W2098640714 @default.
• W2079433130 cites W2100708741 @default.
• W2079433130 cites W2104906182 @default.
• W2079433130 cites W2110891275 @default.
• W2079433130 cites W2112558234 @default.
• W2079433130 cites W2113855026 @default.
• W2079433130 cites W2128628566 @default.
• W2079433130 cites W2131786551 @default.
• W2079433130 cites W2142429004 @default.
• W2079433130 cites W2144691110 @default.
• W2079433130 cites W2145088312 @default.
• W2079433130 cites W2148848488 @default.
• W2079433130 cites W2151444534 @default.
• W2079433130 cites W2151503957 @default.
• W2079433130 cites W2152274262 @default.
• W2079433130 cites W2153106656 @default.
• W2079433130 cites W2153553059 @default.
• W2079433130 cites W2153837873 @default.
• W2079433130 cites W2155772361 @default.
• W2079433130 cites W2159876545 @default.
• W2079433130 cites W2165385395 @default.
• W2079433130 cites W2171302499 @default.
• W2079433130 cites W4233420143 @default.
• W2079433130 cites W2165805761 @default.
• W2079433130 doi "https://doi.org/10.1158/1078-0432.ccr-14-1688" @default.
• W2079433130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25609059" @default.
• W2079433130 hasPublicationYear "2015" @default.
• W2079433130 type Work @default.
• W2079433130 sameAs 2079433130 @default.
• W2079433130 citedByCount "36" @default.
• W2079433130 countsByYear W20794331302015 @default.
• W2079433130 countsByYear W20794331302016 @default.
• W2079433130 countsByYear W20794331302017 @default.
• W2079433130 countsByYear W20794331302018 @default.
• W2079433130 countsByYear W20794331302019 @default.
• W2079433130 countsByYear W20794331302020 @default.
• W2079433130 countsByYear W20794331302021 @default.
• W2079433130 countsByYear W20794331302022 @default.
• W2079433130 countsByYear W20794331302023 @default.
• W2079433130 crossrefType "journal-article" @default.
• W2079433130 hasAuthorship W2079433130A5015636061 @default.
• W2079433130 hasAuthorship W2079433130A5022969007 @default.
• W2079433130 hasAuthorship W2079433130A5025533934 @default.
• W2079433130 hasAuthorship W2079433130A5040594896 @default.
• W2079433130 hasAuthorship W2079433130A5044250695 @default.
• W2079433130 hasAuthorship W2079433130A5052266547 @default.
• W2079433130 hasAuthorship W2079433130A5055703421 @default.
• W2079433130 hasAuthorship W2079433130A5067193071 @default.
• W2079433130 hasAuthorship W2079433130A5072885632 @default.
• W2079433130 hasAuthorship W2079433130A5077480042 @default.
• W2079433130 hasAuthorship W2079433130A5079394240 @default.
• W2079433130 hasAuthorship W2079433130A5083948167 @default.
• W2079433130 hasAuthorship W2079433130A5085470464 @default.

• next